Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics       

NEKTAR THERAPEUTICS
My previous session
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

NEKTAR THERAPEUTICS : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2018 | 11:04pm CEST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(e) Compensatory Arrangements with Certain Officers.

The Board of Directors (the "Board") of Nektar Therapeutics, a Delaware corporation (the "Company"), previously approved an amendment and restatement of the Nektar Therapeutics 2017 Performance Incentive Plan (the "2017 Plan"), subject to stockholder approval, to increase the available shares under the 2017 Plan, as amended and restated (the "Amended 2017 Plan"), by 10,900,000 shares for a total share reserve of 19,200,000 shares. In addition, the amendment and restatement modified the 2017 Plan to reflect the repeal of the performance-based compensation exemption under Section 162(m) of the Internal Revenue Code of 1986, as amended. As disclosed in Item 5.07 of this Current Report on Form 8-K, the Company's stockholders approved the Amended 2017 Plan at the Annual Meeting of Stockholders of the Company held on June 26, 2018 (the "Annual Meeting").

The following summary of the Amended 2017 Plan is qualified in its entirety by reference to the text of the Amended 2017 Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

The Board or one or more committees appointed by the Board will administer the Amended 2017 Plan. The Board has delegated general administrative authority for the Amended 2017 Plan to the compensation committee of the Board. The administrator of the Amended 2017 Plan has broad authority under the Amended 2017 Plan to, among other things, select participants and determine the type(s) of award(s) that they are to receive, and determine the number of shares that are to be subject to awards and the terms and conditions of awards, including the price (if any) to be paid for the shares or the award.

Persons eligible to receive awards under the Amended 2017 Plan include directors of the Company, officers or employees of the Company or any of its subsidiaries, and certain consultants and advisors to the Company or any of its subsidiaries.

The maximum number of shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), that may be issued or transferred pursuant to awards under the Amended 2017 Plan equals 19,200,000 shares. Shares issued in respect of any "full-value award" granted under the Amended 2017 Plan will be counted against the share limit described in the preceding sentence as 1.50 shares for every one share actually issued in connection with the award. For example, if the Company granted 100 shares of Common Stock under the Amended 2017 Plan, 150 shares would be charged against the share limit with respect to that award. For this purpose, a "full-value award" means any award granted under the plan other than a stock option or stock appreciation right.

The following other limits are also contained in the Amended 2017 Plan: (1) the maximum number of shares that may be delivered pursuant to options qualified as incentive stock options granted under the plan is 19,200,000 shares; (2) the maximum number of shares subject to options and stock appreciation rights that are granted during any calendar year to any individual under the plan is 3,000,000 shares; (3) performance-based awards under Section 5.2 of the Amended 2017 Plan granted to a participant in any one calendar year will not provide for payment of more than (a) in the case of awards payable only in cash and not related to shares, $5,000,000, and (b) in the case of awards related to shares (and in addition to options and stock appreciation rights which are subject to the limit referred to above), 3,000,000 shares; and (4) the aggregate value of cash compensation and the grant date fair value (computed in accordance with generally accepted accounting principles) of shares of Common Stock that may be paid or granted during any calendar year to any non-employee director shall not exceed $1,200,000 for existing non-employee directors and $2,200,000 for new non-employee directors.

The types of awards that may be granted under the Amended 2017 Plan include stock options, stock appreciation rights, restricted stock, stock bonuses and other forms of awards granted or denominated in Common Stock or units of Common Stock, as well as certain cash bonus awards.

As is customary in incentive plans of this nature, each share limit and the number and kind of shares available under the Amended 2017 Plan and any outstanding awards, as well as the exercise or purchase prices of awards, and performance targets under certain types of performance-based awards, are subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, stock splits, stock dividends, or other similar events that change the number or kind of shares outstanding, and extraordinary dividends or distributions of property to the stockholders.


Item 5.07     Submission of Matters to a Vote of Security Holders


At the Annual Meeting, the following actions were taken. The proposals below are described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2018.







Proposal 1


Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the Board until the Company's 2021 Annual Meeting of Stockholders.

Nominee For Against Abstain Broker Non-Votes Jeff Ajer 140,999,178 827,183 126,420 13,373,797 Robert B. Chess 137,004,118 4,816,469 132,194 13,373,797 Roy A. Whitfield 134,045,472 7,671,584 235,725 13,373,797

In addition to the directors elected above, R. Scott Greer, Christopher A. Kuebler, Lutz Lingnau, Howard W. Robin, and Dennis L. Winger continue to serve as directors after the Annual Meeting.



Proposal 2


The proposal to approve the Amended 2017 Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 10,900,000 shares to a total share reserve of 19,200,000 shares was approved with approximately 95% of the shares present or represented and voting at the Annual Meeting voting for the proposal and approximately 5% voting against the proposal.




    For      Against  Abstain
134,318,917 7,507,246 126,618




Proposal 3


The proposal to ratify the appointment, by the audit committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018 was approved with approximately 99% of the shares present or represented and voting at the Annual Meeting voting for the proposal and approximately 1% voting against the proposal.




    For     Against Abstain
154,097,408 837,955 391,215




Proposal 4


The proposal to approve the compensation of the Company's Named Executive Officers, on a non-binding advisory basis, was approved with approximately 92% of the shares present or represented and voting at the Annual Meeting voting for the proposal and approximately 8% voting against the proposal.




    For      Against   Abstain
129,678,867 11,907,345 366,569


Item 9.01     Financial Statements and Exhibits.



(d)     Exhibits.



Exhibit    Description
  No.

  10.1       Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEKTAR THERAPEUTICS
10/04Investigation of Nektar Therapeutics Announced by Holzer & Holzer
BU
10/03NEKTAR THERAPEUTICS : NKTR) Investigated by Block & Leviton LLP For Violations o..
PR
10/03Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Thera..
PR
10/02NEKTAR THERAPEUTICS : Announces Ten Abstracts Accepted for Presentation at the 2..
PR
10/02Nektar falls on short seller report
AQ
10/02NEKTAR THERAPEUTICS : Strengthens Board of Directors with Appointment of Veteran..
PR
10/01NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
09/24NEKTAR THERAPEUTICS : BioXcel Therapeutics Expands Immuno-Oncology Partnership w..
AQ
08/09NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
08/08NEKTAR : 2Q Earnings Snapshot
AQ
More news
News from SeekingAlpha
07/12ROUNDS REPORT : Aveo Catches A Big Payday With NHSScotland Approval Of Tivozanib 
07/06S&P 1500 Misfit Stocks 
07/06Biogen leads biotechs into positive territory 
07/05ROUNDS REPORT : Adamis Rallied Due To A Commercialization Partnership 
06/29ROUNDS REPORT : Nektar Positioned As A Stellar Buying Opportunity Amid Strong Ma.. 
Financials ($)
Sales 2018 1 181 M
EBIT 2018 692 M
Net income 2018 669 M
Finance 2018 469 M
Yield 2018 -
P/E ratio 2018 13,34
P/E ratio 2019
Capi. / Sales 2018 6,99x
Capi. / Sales 2019 29,5x
Capitalization 8 725 M
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 89,4 $
Spread / Average Target 77%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer, Senior R&D
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS-18.40%8 725
CELLTRION, INC.--.--%29 133
IQVIA HOLDINGS INC26.93%25 281
LONZA GROUP18.00%23 235
INCYTE CORPORATION-34.51%13 299
SEATTLE GENETICS, INC.36.58%11 555